Table 1.
Comparison of the effect of treatment on changes in bone mineral density (BMD) and bone turnover markers (BTM) in people with and without T2D in nine bisphosphonate trials
| Non-DM | T2D | Interaction pa | |||
|---|---|---|---|---|---|
| N | Mean (95% CI) | N | Mean (95% CI) | ||
| % Difference in BMD change (active-placebo) at 24 months | |||||
| Total hip | 17,612 | 3.66 (3.53–3.78) | 716 | 4.08 (3.42–4.75) | 0.20 |
| Femoral neck | 19,869 | 2.89 (2.74–3.04) | 791 | 3.13 (2.27–3.99) | 0.57 |
| Lumbar spine | 13,054 | 4.33 (4.17–4.49) | 385 | 4.62 (3.76–5.47) | 0.46 |
| % Difference in BTM change at 3 to 12 months (active-placebo) | |||||
| CTX | 5789 | − 52.1 (− 53.7, − 50.5) | 197 | − 51.1 (− 59.8, − 40.5) | 0.88 |
| P1NP | 7094 | − 50.3 (− 51.4, − 49.2) | 265 | − 44.2 (− 50.6, − 36.9) | 0.09 |
| NTX/Cr | 3774 | − 37.6 (− 39.8, − 35.2) | 119 | − 41.5 (− 51.5, − 29.3) | 0.53 |
All results are adjusted for trial
BMD bone mineral density, BTM bone turnover marker, CTX serum C-terminal cross-linking telopeptide, NTX/Cr urinary N-telopeptide of type I collagen/creatinine, P1NP serum procollagen type I N-propeptide
a2-way interaction: Treatment × Diabetes status
Reproduced with permission from Eastell et al. [20]